Addendum

Nivolumab/relatlimab (melanoma) – Addendum to Project A26-65

Status
Status: Commission completed
Project no.
A26-120
Last updated

Report documents

  1. Addendum

    Nivolumab/relatlimab (melanoma) – Addendum to Project A26-65

    published on
    Document type
    PDF document, 351 kB, DE, not accessible
    DOI-Link
    https://doi.org/10.60584/A26-120

Dossier assessment

Indication:

Adults and adolescents 12 years of age and older with advanced (unresectable or metastatic) melanoma with tumour cell programmed cell death ligand 1 expression <1%; first-line treatment

Result of dossier assessment:
  • Adults: unchanged after addendum: hint of a minor added benefit
  • Adolescents 12 years of age and older: unchanged after addendum: added benefit not proven

Additional information

Federal Joint Committee (GBA)

19-11-2026 A G-BA decision was published.
GBA documents on this decision

Project details

Project no.
A26-120
Commission
Commission awarded on 06.10.2026 by the Federal Joint Committee (GBA).
Report type
Addendum
Status
Commission completed
Department/Division
Drug Assessment
Topic
Cancer
Note

If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.

DOI

https://doi.org/10.60584/A26-120

Connected Projects

  1. Dossier assessment

    Nivolumab/relatlimab (melanoma) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A26-65
    Last updated

    Status: Commission completed

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form